Detecting rare diseases in electronic health records using machine learning and knowledge engineering: Case study of acute hepatic porphyria

Aaron M Cohen; Steven Chamberlin; Thomas Deloughery; Michelle Nguyen; Steven Bedrick; Stephen Meninger; John J Ko; Jigar J Amin; Alex J Wei; William Hersh

doi:10.1371/journal.pone.0235574

. 2020 Jul 2;15(7):e0235574. doi: 10.1371/journal.pone.0235574

Detecting rare diseases in electronic health records using machine learning and knowledge engineering: Case study of acute hepatic porphyria

Aaron M Cohen ^1,^*, Steven Chamberlin ¹, Thomas Deloughery ¹, Michelle Nguyen ¹, Steven Bedrick ¹, Stephen Meninger ², John J Ko ², Jigar J Amin ², Alex J Wei ², William Hersh ¹

Editor: Sreeram V Ramagopalan³

¹Department of Medical Informatics & Clinical Epidemiology, School of Medicine, Oregon Health & Science University, Portland, Oregon, United States of America

²Alnylam Pharmaceuticals, Cambridge, Massachusetts, United States of America

³University of Oxford, UNITED KINGDOM

Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: GIVLAARI is a product of Alnylam. GIVLAARI is a prescription medicine used to treat acute hepatic porphyria (AHP) in adults. This work was funded and the associated editorial support was provided by Alnylam Pharmaceuticals, Inc., Cambridge, MA. Grant number 4510005336, https://www.alnylam.com/ Alnylam participated in algorithm design and preparation of the manuscript. They had no role in the evaluation or EHR data collection and analysis, nor did they have any access to the individual patient electronic health record data used in this research. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

^✉

* E-mail: cohenaa@ohsu.edu

Roles

Aaron M Cohen: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing

Steven Chamberlin: Data curation, Validation, Writing – original draft, Writing – review & editing

Thomas Deloughery: Data curation, Funding acquisition, Methodology, Validation

Michelle Nguyen: Data curation

Steven Bedrick: Conceptualization, Software, Writing – review & editing

Stephen Meninger: Funding acquisition, Investigation, Resources, Validation, Writing – review & editing

John J Ko: Conceptualization, Funding acquisition, Supervision, Writing – review & editing

Jigar J Amin: Conceptualization, Funding acquisition, Project administration, Writing – review & editing

Alex J Wei: Conceptualization, Funding acquisition, Writing – review & editing

William Hersh: Conceptualization, Data curation, Funding acquisition, Methodology, Supervision, Validation, Writing – original draft, Writing – review & editing

Sreeram V Ramagopalan: Editor

PMCID: PMC7331997 PMID: 32614911

Abstract

Background

With the growing adoption of the electronic health record (EHR) worldwide over the last decade, new opportunities exist for leveraging EHR data for detection of rare diseases. Rare diseases are often not diagnosed or delayed in diagnosis by clinicians who encounter them infrequently. One such rare disease that may be amenable to EHR-based detection is acute hepatic porphyria (AHP). AHP consists of a family of rare, metabolic diseases characterized by potentially life-threatening acute attacks and chronic debilitating symptoms. The goal of this study was to apply machine learning and knowledge engineering to a large extract of EHR data to determine whether they could be effective in identifying patients not previously tested for AHP who should receive a proper diagnostic workup for AHP.

Methods and findings

We used an extract of the complete EHR data of 200,000 patients from an academic medical center and enriched it with records from an additional 5,571 patients containing any mention of porphyria in the record. After manually reviewing the records of all 47 unique patients with the ICD-10-CM code E80.21 (Acute intermittent [hepatic] porphyria), we identified 30 patients who were positive cases for our machine learning models, with the rest of the patients used as negative cases. We parsed the record into features, which were scored by frequency of appearance and filtered using univariate feature analysis. We manually choose features not directly tied to provider attributes or suspicion of the patient having AHP. We trained on the full dataset, with the best cross-validation performance coming from support vector machine (SVM) algorithm using a radial basis function (RBF) kernel. The trained model was applied back to the full data set and patients were ranked by margin distance. The top 100 ranked negative cases were manually reviewed for symptom complexes similar to AHP, finding four patients where AHP diagnostic testing was likely indicated and 18 patients where AHP diagnostic testing was possibly indicated. From the top 100 ranked cases of patients with mention of porphyria in their record, we identified four patients for whom AHP diagnostic testing was possibly indicated and had not been previously performed. Based solely on the reported prevalence of AHP, we would have expected only 0.002 cases out of the 200 patients manually reviewed.

Conclusions

The application of machine learning and knowledge engineering to EHR data may facilitate the diagnosis of rare diseases such as AHP. Further work will recommend clinical investigation to identified patients’ clinicians, evaluate more patients, assess additional feature selection and machine learning algorithms, and apply this methodology to other rare diseases. This work provides strong evidence that population-level informatics can be applied to rare diseases, greatly improving our ability to identify undiagnosed patients, and in the future improve the care of these patients and our ability study these diseases. The next step is to learn how best to apply these EHR-based machine learning approaches to benefit individual patients with a clinical study that provides diagnostic testing and clinical follow up for those identified as possibly having undiagnosed AHP.

Introduction

The growing adoption of the electronic health record (EHR) worldwide has created new opportunities for leveraging EHR data for other, so called secondary purposes, such as clinical and translational research, quality measurement and improvement, patient cohort identification and more [1]. One emerging use case for leveraging of EHR data is to detect undiagnosed rare diseases. Although there is no absolute definition of a rare disease, the US Rare Diseases Act of 2002 defines rare diseases as those that occur in fewer than 200,000 patients worldwide, and the National Organization for Rare Disorders (NORD,) registry lists more than 1,200 diseases. Others have noted that the true number of rare diseases is unknown, and have called for more research to define them [2].

Rare diseases can be difficult to diagnose because their infrequent occurrence may result in primary care physicians not considering them in diagnostic workups [3]. They also often have general presentations with diffuse symptoms, as well as genetic components which may require specialized testing. This lack of timely diagnosis may lead to both physical and emotional suffering as patients remain undiagnosed for prolonged periods. Additionally, a lack of accurate diagnoses increases economic burden to healthcare systems as patients continue to receive inadequate and/or inappropriate treatment. Some informatics researchers have used EHR data to detect rare diseases, such as cardiac amyloidosis [4], lipodystrophy [5], and a large collection of different diseases [6, 7].

One rare disease that may be amenable to EHR-based detection is acute hepatic porphyria (AHP). AHP is a subset of porphyria that refers to a family of rare, metabolic diseases characterized by potentially life-threatening acute attacks and, for some patients, chronic debilitating symptoms that negatively impact daily functioning and quality of life [8–12]. During attacks, patients typically present with multiple signs and symptoms due to dysfunction across the autonomic, central, and peripheral nervous systems. The prevalence of diagnosed symptomatic AHP patients is ~1 per 100,000 [13]. Due to the nonspecific symptoms and the rare nature of the disease, AHP is often initially overlooked or misdiagnosed. A U.S. study demonstrated that diagnosis of AHP is delayed on average by up to 15 years [14].

AHP is predominantly caused by a genetic mutation leading to a partial deficiency in the activity of one of the eight enzymes responsible for heme synthesis [11]. These defects predispose patients to the accumulation of neurotoxic heme intermediates aminolevulinic acid (ALA) and porphobilinogen (PBG) when the rate limiting enzyme of the heme synthesis pathway, aminolevulinic acid synthase 1 (ALAS1), is induced [10, 14]. Gene mutations causing the disease are mostly autosomal dominant, however the disease has low penetrance (~1%) and many specific mutations have not been identified [15]. Furthermore, families carrying the gene may have few or only one affected member. Therefore, family history can be a poor diagnostic tool for this disease. The preferred diagnostic procedure for AHP is biochemical testing of random/spot urine for ALA, PBG, and porphyrin [16, 17].

Historically, treatment of AHP has predominantly focused on avoidance of attack triggers, management of pain and other chronic symptoms, and treatment of acute attacks through the use of Panhematin^® (hemin for injection) [18]. Panhematin was FDA approved in 1983 for the amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporally related to the menstrual cycle in susceptible women after initial carbohydrate therapy is known or suspected to be inadequate.

Recently, a new drug Givlaari^® (givosiran), for subcutaneous injection has been approved by the FDA for the treatment of adults with AHP. Givosiran is a double-stranded small interfering RNA (siRNA) molecule that reduces induced levels of the protein ALAS1. A Phase 1 trial has been published [19] and a Phase 3 randomized control trial has shown this therapy to be effective in reducing the occurrence of acute attacks and impacting other manifestations of the disease [20].

The goal of this study was to apply machine learning and knowledge engineering to a large extract of EHR data to determine whether the combined approach could be effective in identifying patients not previously tested for AHP who should receive a proper diagnostic workup for AHP.

Materials and methods

Dataset

Oregon Health & Science University (OHSU) is the only academic medical center in Oregon and is thus a referral center for rare diseases like AHP. The OHSU Research Data Warehouse (RDW) is a research data “honest broker” service that provides EHR data to researchers, with appropriate IRB approval. The investigators have an ongoing institutional review board (IRB) approval to use an extract from the Oregon Health & Science University (OHSU) EHR research data warehouse (RDW) for a series of patient cohort identification projects. For this research, the patient cohort to identify was defined as those patients who have a documented clinical history of AHP, or a clinical history indicating that AHP diagnostic testing may be appropriate.

A large dataset of approximately 200,000 patient records was requested from the RDW, complete as of the data pull date in March 2019, including over 30 million text notes plus other document types. The data set goes back to the start of OHSU using the Epic EHR system in January, 2009. These records consist of all patients who had more than one primary care health care visit at our institution. Each patient record was represented as a collection of documents of types given in Table 1. Patient records could include zero or more documents of each type.

Table 1. Electronic Health Record (EHR) document types used in this research.

EHR Document Record Type	Description of Document
Administered Medications	Medications given to patient during a hiospital stay or ambulatory encounter.
Current Medications	The concomittent medications a patient is taking, as documented by providers during encounters.
Demographics	Patient demographic information
Encounter Diagnosis	The diagnoses and diagnostic codes assigned to a patient ambulatory encounter.
Hospital Encounters	Patient-level hospital admission information including times and billing codes.
Lab Results	Results of ordered lab tests including order time.
Medications Ordered	Medications ordered by for patients by clinicians during an encounter.
Microbiology Results	Results of microbiology lab tests in text form.
Notes	All types of clinical text including progress notes and discharge summaries.
Problem List	The concomittent list of active medical issues for a patient, as documented by providers during encounters.
Procedures Ordered	Procedures ordered by clinicians for patients during an encounter.
Lab Result Comments	Non-numerical, text portion, if any for results of lab tests.
Surgeries	Description of surgeries performed on patient at hospital in both text and coded forms.
Vitals	Documentation of vital values such as heartrate, blood pressure, weight, and temperature.

Open in a new tab

To insure an adequate sample size to make predictive models robust, we enriched the data set for possible AHP by adding records from an additional 5,571 patients who met one or more of the following case-insensitive criteria (see Table 2):

Table 2. Electronic Health Record (EHR) total document and unique patients counts of porphyria codes and mentioned in text notes or label tests.

Counts shown here are out of a total of 347,709,284 individual EHR documents and 204, 413 total unique patient records.

Code	Total Documentsts	Total Patientsents
ICD9 277.1	3879	308
E80.0 Hereditary erythropoietic porphyria	472	37
E80.1 Porphyria cutanea tarda	783	77
E80.20 Unspecified porphyria	2010	247
E80.21 Acute intermittent (hepatic) porphyria	1016	47
E80.29 Other porphyria	109	24
E80.4 Gilbert syndrome	3197	366
E80.6 Other disorders of bilirubin metabolism	9502	2308
E80.7 Disorder of bilirubin metabolism, unspecified	75	58
Patients with porphyria mentioned in a lab test:	359	175
Searching field NOTE_TEXT for term porphyria:	14353	3012

Open in a new tab

Diagnosis including the wildcard search term “porph*” in the diagnosis name
Medication including the wildcard search term “hemin*” in the medication name
Procedure including the wildcard search term “porph*” in the procedure name
Clinical or result note including the wildcard search term “porph*” in the note text

These 5,571 patient records were pulled from the RDW at the same time and in the same format as the 200K patients. There may have been some overlap between this set of patients and the 200K patients, before this data was merged into a single data set. However, all records were grouped by patient and an individual patient was only counted as a single sample in the merged data set.

To develop a gold standard for the data, a medical student (MN), overseen by clinical experts among the rest of the authors, conducted a chart review to identify patients with a confirmed diagnosis of AHP. We manually reviewed all the patients with the ICD-10-CM code E80.21 (Acute intermittent [hepatic] porphyria) in their record, looking for positive confirmation of AHP either through a lab test or a specific comment in a progress note. This process yielded 30 positive cases from the 47 coded for E80.21. As OHSU is the only academic medical center in Oregon and is thus a referral center for rare diseases like AHP, this may explain why the number of identified AHP patients in our database was higher than that which would be expected based on the global prevalence of AHP. For the remaining 17 records, we could not confirm by chart review the diagnosis of AHP. This may be due to the code being attached to the patient based on an encounter to rule out AHP, inaccurate past medical history data, or a charting error. For these 17 patients no additional information supporting the AHP diagnosis was found in the notes, clinical tests or medication records and the only evidence of AHP was an ICD-10-CM code at one place in the medical record.

The rest of the records were then assumed to be negative for AHP for the purposes of statistical analysis and machine learning. The data set consisted of the positive records plus the presumed negative records. The entire data set was used for statistical analysis and training the machine learning models, the final goal of which was to identify the presumed negative records which are actually likely to be positive.

We then deconstructed each patient record into a number of features to be used for machine learning. Structured data fields were encoded directly with the entire field content used as the feature. Free-text fields were parsed into unigrams and bigrams.

All features were labeled with their source document fields. This enabled, for example, diagnosis names in ICD-10-CM code fields in the problem list to be distinguished from the same text appearing in free text notes. Feature values were encoded as the number of occurrences in the entire record for the patient. A summary of the types and counts of documents in the data set is shown in Table 3.

Table 3. Summary of document types and counts used in the EHR data set for this research.

Document Type	Patients	Encounters	Records	Median	Max
Current Medications	187724	N/A	99602443	89	57406
Demographics	204413	N/A	204413	1	1
Encounter Attributes	204412	19589057	19589057	43	3335
Encounter Diagnoses	202843	10113657	52295188	69	27215
Hospital Encounters	145551	1163284	1163284	3	520
Lab Results	172795	2012185	58386934	84	27384
Ordered Medications	190256	3964120	15155203	23	7041
Microbiology Results	54798	145528	1988429	5	5174
Notes	204161	10014987	28938900	56	14933
Problem List	181221	N/A	1737749	6	204
Procedures Ordered	198833	5129756	19501225	31	35364
Result Comments	131104	896896	1542279	4	1765
Surgeries	44238	78403	83535	1	54
Vitals	199971	3500418	18268032	24	9442
Administered Medications	100565	349332	17160858	17	53178
Ambulatory Encounters	204235	12091755	12091755	27	1991

Open in a new tab

Feature selection and machine learning methods

Features to be included in the machine learning model were selected by performing univariate logistic regression analysis of the entire feature set, using the confirmed AHP patients as positive samples and the rest of the data set as negative samples.

For each document type, the 100 top features were chosen, ranked by odds ratio, having a p-value < 0.01 and occurring in at least 4 positive case patient records. This statistical criteria was used to establish which data elements had a significant relationship between the outcome variable, which was the presence, or not, of a confirmed diagnosis of AHP. Univariate analysis was performed so that individual variables could be analyzed for statistical significance and manually reviewed independently to create a smaller starting set for multivariate machine learning. Requiring that included features have at least four positive case patient records was chosen as a filter to strike a balance between only keeping the most common features, and keeping thousands of rare features requiring manual review that were unlikely be helpful in a generalized model.

From these several hundred features, a manual review process was performed to ensure that none of these features were directly connected to a diagnosis of AHP, mention of AHP in the record, or treatment of AHP. This was done by inspection. This process eliminated all text features mentioning any bigram of “acute hepatic porphyria,” medications such as hematin, and laboratory codes that in the OHSU system represented tests specifically for the diagnosis of porphyria.

The remaining features were then evaluated by using them in a machine learning model and scoring the model using 5 repetitions of 2-fold cross-validation. Several SVM kernel functions were tested including linear, polynomial degree 2, and the radial basis function (RBF), random forests, Adaboost, J48, and several topologies of Neural Network. Two normalization encoding methods were tried as well, binary, linear and log normalizing feature occurance counts beween 0.0 and 1.0.

After algorithm selection, a second round of feature screening was performed. Any features with non-zero algorithm weights were removed if any direct connection to AHP could be established. This was performed by close scrutiny and discussion with our clinical expert for each feature. This second pass incorporated a higher level of clinical expertise than the first pass. It was performed after filtering by machine learning weights in order to reduce the burden of manual chart review on our clinical expert.

Machine learning for AHP prediction and evaluation methodology

A final trained model using the features selected was created by training the selected algorithm with chosen parameter settings on the entire data set. This model was then applied back to the entire data set in order to create an AHP prediction score for each patient. The classifier margin distance was taken as the prediction score. Standard SVM boundary settings were used, keeping samples scores inside the boundary region within the interval [-1, +1].

The patient prediction scores were then analyzed. To keep the manual chart review process manageable, we could not review every patient. We decided to review the top scoring 100 cases manually from each of two subsets of the general population. An alternative method would be a randomly selected subset of patients for chart review. However, because AHP is such as rare disease, the probability of finding even a single positive case with random sampling would is very small, about 0.05%.

The first reviewed subset of 100 patients were those with no mention of porphyria in their chart, no related ICD-9-CM or ICD-10-CM codes, and no porphyria specific lab test. We selected the top scoring 100 patients that met these criteria. This represents the most important target population for our project–patients with persistent symptoms that have not had AHP considered and tested to rule it in or out as a diagnosis. Manual review of these cases is intended to demonstrate the potential of our proposed approach to identify potential cases of AHP that would benefit from diagnostic testing and follow up.

The second reviewed subset of 100 patients were those with a mention of porphyria in the text notes in their chart, but no related ICD-9-CM or ICD-10-CM diagnosis codes, and no porphyria-specific lab test. These are patients where porphyria may have been considered by the clinician, or may have been tested at another health care facility with unavailable records, or may have been a work up in progress. Manual review of these cases was intended to discern the clinical face validity of the algorithmic predictions, that is, the high scoring patients in this group score high because the algorithm is paying attention to some of the same non-AHP-specific clinical symptoms and other variables as the clinician. While the manual review of these patients was primarily intended for gaining insight into how the algorithm was scoring patients with porphyria mentioned in the charts, based on the manual review some patients who may benefit from diagnostic testing could be found.

A clinically trained reviewer assessed the patients’ records in these two non-overlapping subsets for symptom patterns consistent with acute hepatic porphyria (AHP). The reviewer was blinded to the model features. Clinical notes were searched for the ‘classic triad’ of AHP symptoms: abdominal pain, central nervous system abnormalities, and peripheral neuropathy [21]. In addition, any report of pain was assessed, and searches were also conducted for the highest incident AHP symptoms: abdominal pain, vomiting, constipation, muscle weakness, psychiatric symptoms, limb, head, neck, or chest pain, hypertension, tachycardia, convulsion, sensory loss, fever, respiratory paralysis, diarrhea [21]. All major comorbidities were also reviewed and documented, as well as alternative diagnoses to explain AHP symptom profiles.

The 100 patients with no mention of porphyria in their EHR record were classified into one of three categories: AHP diagnostic testing likely indicated, AHP diagnostic testing possibly indicated, and AHP diagnostic testing unlikely indicated. To be classified as likely, symptoms had to be present in all three categories of the ‘classic triad’, without a cause identified in the EHR, and with a substantial history of symptoms. To be classified as possibly, symptoms had to be present in at least one of the three categories, without a cause documented and with a substantial history. Patients were classified as unlikely if their symptoms could be explained by another diagnosis, or if they did not have a strong AHP symptom profile.

The 100 patients who did have a mention of porphyria in their clinical notes were classified into one of five categories of AHP status based on chart review and details in the clinical notes: AHP already suspected, AHP already suspected but ruled out, diagnostic testing likely indicated but AHP not suspected, unlikely AHP, and AHP diagnosis mentioned in notes. A patient was classified as AHP already suspected if there was any level of AHP suspicion mentioned in their clinical notes, without a formal diagnosis or lab test. AHP already suspected but ruled out was assigned if there was a suspicion of AHP in the note, but had been ruled out, usually by negative lab tests. These lab tests were only documented in the note, since we excluded patients from this subset who had lab tests in the laboratory data itself. Diagnostic testing likely indicated but AHP not suspected was assigned if there were symptoms present in at least one of the three triad categories, without a cause, but no suspicion of AHP mentioned in the notes. For these patients the clinical notes contained the string ‘porph’ but presence of ‘porph’ in the clinical note was not related to suspicion of AHP. Unlikely AHP was assigned if AHP type symptoms could be explained by another diagnosis, or there was not a strong AHP symptom profile. Finally, patients were assigned to AHP diagnosis if there was any mention of an existing AHP diagnosis in the notes, even patient reported. The reasons for the presence of the string ‘porph’ in the clinical note for the second set of 100 patients was also reviewed and documented. Patient’s categorized as AHP already suspected and Diagnostic testing likely indicated but AHP not suspected would benefit from AHP testing as they displayed suspicion of AHP or symptom complexes associated with AHP but have yet received a full diagnostic work-up.

This study protocol was approved by the OHSU Institutional Review Board (IRB00011159).

Results

Final selected features and machine learning cross-validation

Fig 1 shows a flowchart of the overall patient record filtering and manual review process. The process starts with 204,413 patient records, and using a combination of machine learning and structured data filtering described above, identifies 200 patients that were manually reviewed. 100 of those patients were identified as not having any mention of porphyria in the medical record and potentially could benefit from AHP diagnostic testing. The other 100 of those patients did have mention of porphyria in their medical record, but no diagnostic code for porphyria. These records were reviewed to determine the reason for the mention of porphyria and evaluate whether these reasons were consistent with the goal of the machine learning to identify patients with symptoms and other clinical features consistent with a possible porphyria diagnosis.

Several hundred features made it through the statistical testing and occurrence frequency filter. From these several hundred features, the manual review process reduced the set to approximately 200 features. These features were then evaluated by using them in a machine learning model and scoring the model using 5 repetitions of 2-fold cross-validation. These experiments found that an SVM with the radial basis function (RBF) kernel scored best for the ranking metrics AUC and average precision. The other machine learning methods explored failed to perform as well as the RBF SVM. It was also determined that feature values were best encoded using log normalization, transforming feature occurrence counts into values between 0.0 and 1.0. Binary encoding, as well as linear normalization, failed to perform as well. We used the SVMLight implementation of the RBF kernel. Experimentation with cross-validation showed gamma = 0.04 to be optimal.

After algorithm selection and tuning, the second round of feature screening removed a few features that the SVM model assigned non-zero weights which were thought to be directly connected to the pre-established diagnosis of AHP by the clinical expert. For example, based on case series evidence, clinical hematology AHP specialists sometimes use cimetidine to treat AHP symptoms, as it is known to block a portion of the heme synthesis pathway as a side effect [22]. We found that cimetidine was a highly weighted feature in our initial models (due to its use by a specialist [TD] at OHSU based on case report data [22]) that had to be removed as it is given in response to AHP rather than being predictive. This process resulted in 141 total features being included in the final model.

The 141 features included in the final model are shown in S1 Table. Final feature set cross-validation performance on the entire training set is shown in Table 4.

Table 4. Cross-validation performance of the final feature set on the entire data set for ranking the 30 confirmed cases of porphyria higher than the general population.

SVM with radial basis function (RBF) kernel and gamma = 0.04.

Metric	Score
AUC	0.775
Average Precision	0.060
Precision @ 100	0.031
Log Loss	0.404

Open in a new tab

Application of machine learning to the full data set

The final machine learning model with the 141 features was trained on the entire data set, and this model was then applied back to the entire data set in order to provide a margin distance score for every patient.

The patient prediction scores were then analyzed. In particular, the range of scores obtained for the 30 confirmed positive training cases were compared to the rest of the patients in the data set. About 22,000 patients in the general population had scores that overlapped with those of the 30 positive patients. While this was only 10% of the patient records, it was more than could be manually reviewed.

We reviewed the top scoring 100 cases manually from each of two subsets of the general population. Out of the 100 patient charts we reviewed with no mention of porphyria, four were identified as likely to AHP diagnostic testing likely indicated, all without mention of porphyria in their medical record or documentation of a urine PBG test. The first patient was a male with six years of unexplained intermittent abdominal pain with nausea, vomiting, and diarrhea. His other conditions included complex regional pain syndrome, peripheral neuropathy, cardiac arrhythmias, panic attacks, and depression. The next patient was a female whose abdominal pain was described as ‘a long standing symptom with extensive negative evaluation’. Also listed in her profile were neuralgias, hereditary small fiber neuropathy, movement disorder, fibromyalgia, migraines, palpitations, and somatization disorder. The third patient was a woman with multiple emergency department admissions for severe abdominal pain. She also had severe suicidality with a permanent tracheostomy due to a hanging attempt, borderline personality disorder, tachycardia, anxiety, saddle anesthesia, insomnia, and severe somatization disorder including a comment in her note advising not to admit the patient for only vague complaints. The fourth patient was a female with a history of abdominal pain comments in the notes describing that the etiology had not been identified for her complex symptomology which included headaches, abdominal pain, paresthesias and palpitations.

Overall, about a quarter of the 100 patients in the group without mention of porphyria had symptom profiles that were consistent with undiagnosed AHP and AHP diagnostic testing would either be likely or possibly indicated (Table 5). In this group there was no sign or suspicion of AHP by the clinician in the record. This is a much higher concentration of possible AHP patients than would be expected by chance based on the known prevlance of AHP.

Table 5. Assessment of the likelihood of undiagnosed acute hepatic porphyria based on clinical note symptom documentation.

Both groups of 100 reviewed patients are listed.

	Acute Hepatic Porphyria?	# Patients
*No mention of porphyria group (n = 100)*	Diagnostic test is Likely Indicated	4
	Diagnostic test is Possibly Indicated	18
	Diagnostic test is Unlikely Indicated	68
	Deceased	10
*‘Porph’ in clinical notes group (n = 100)*	Suspected in chart	16
	Suspected, ruled out in chart	15
	Diagnostic test is Possibly Indicated, not suspected in chart	4
	Unlikely based on chart review	54
	Diagnosed, documented in chart	4
	Unknown, unable to determine	1
	Deceased	6

Open in a new tab

Alternate explanations for characteristic AHP symptom profiles were diverse in the patient group without any mention of porphyria (Table 6). Cancers seen in this group included breast, uterine, pancreatic, cervical, leukemia and adrenal carcinoma. Other common comorbidities and conditions seen in this group included: fibromyalgia, irritable bowel syndrome, chronic fatigue, obesity, hypertension, obstructive sleep apnea, and chronic obstructive pulmonary disease. In contrast, alternate symptom profiles in the group with mention of porphyria in the notes were dominated by liver pathologies, mostly hepatocellular carcinoma.

Table 6. Top alternative explanations for AHP symptom profiles seen in each group of patients.

Conditions seen in no more than one patient are not listed.

	Alternate AHP Symptom Explanation	# Patients
*No mention of porphyria group*	Surgery	8
	Inflammatory Bowel Disease	6
	Cancer	6
	Cancer Chemotherapy	5
	Gallbladder Pathology	4
	Diabetes	3
	Carnitine Palmitoyl Transferase Deficiency	2
	Renal	4
	Poly Cystic Ovarian Syndrome	2
	Appendicitis	2
	Mastocytosis	2
*‘Porph’ in clinical notes group*	Liver Pathology	30
	Chemotherapy/Drug Side Effects	3
	Mastocytosis	2

Open in a new tab

Patients in the group without mention of porphyria in the medical record generally had much longer and more complicated histories compared to the other group, with 86 out of 100 having encounters spread over four years or longer. The patients with porphyria mentioned in the clinical notes tended to have shorter, and less complex histories (only 39 out of 100 had over 4 years of encounters), more focused on a single medical issue or set of symptoms, which may have been due to their being referral to our academic medical center from other health care sites.

There were small differences in age summary statistics between the two groups (Table 7), but notably more pediatric patients in the reviewed group with mention of porphyria found in clinical notes than those without (10 patients vs 1 patient). There were significantly more male patients found in this group too, compared to the group with no mention of porphyria (Table 8). Associated conditions for these 44 male patients were dominated by only a few diagnoses/symptom patterns: liver disease (N = 18), suspicion of porphyria (N = 11), or actinic keratosis (N = 3). In contrast, no single condition dominated the male disease distribution in the patient group without mention of porphyria in the notes.

Table 7. Age statistics in years for each of the two patient groups.

	MEDIAN	MEAN	STANDARD DEVIATION	MIN	MAX
NO MENTION OF PORPHYRIA	51	53	17.89	8	91
‘PORPH’ IN CLINICAL NOTES	54	50	21.81	6	91

Open in a new tab

Table 8. Sex distribution for each of the two patient groups.

	MALE	FEMALE
NO MENTION OF PORPHYRIA	25	75
‘PORPH’ IN CLINICAL NOTES	44	56

Open in a new tab

About a third of patients in the group with mention of porphyria in the clinical notes had some level of suspicion and work-up for AHP documented. We also identified four patients in this group that we thought had possibly undiagnosed AHP, without suspicion documented in the notes. We labeled these patients as Diagnostic testing likely indicated but AHP not suspected. Three of these patients had ‘porphyria’ in their clinical note listed as a standard precaution for several different medications (hydrochloroquinone, ferrous sulfate), which they were taking. In fact, about two thirds of the patients with ‘porphyria’ in the clinic notes had other reasons, besides suspicion of AHP, for the presence of this word (Table 9). A large number of these patients were candidates for liver transplantation. Standard clinical documentation for evaluation for this procedure included a list of possible causes of liver failure, including protoporphyria. Porphyria was also mentioned as a precaution for certain medications or treatments given to some patients in this group, which included hydroxycholorquinone ferrous sulfate, therapeutic abortion, and UV light therapy for actinic keratosis.

Table 9. Top reasons for the presence of the word ‘porph’ found in the clinical note.

More Common Reasons for ‘Porph’ in Clinical Notes	# Patients
Suspicion of Porphyria	31
Liver Transplant Documentation	30
Porphyria Mentioned in Treatment Precautions	18
Porphyria Diagnosis Mentioned in Notes	4
Porphyria Lab Tests Listed for Screening Physical	3
Family History of Porphyria	5
Misspelling	2

Open in a new tab

Discussion

This work identified four likely and 18 possible patients who had no mention of porphyria in their charts for whom AHP diagnostic testing could be indicated. In addition, four patients who had mention of porphyria in their charts not related to a diagnostic evaluation of the disease were also found likely to have AHP diagnostic testing indicated. This number of patients with indications for AHP diagnostic testing and possibly to-be confirmed diagnosis vastly exceeds that due to chance and surpassed our expectations. It will require clinical follow-up to determine whether these patients’ symptoms are truly due to AHP or not, but the manual record review clearly demonstrates that our methodology has found patients for whom a spot urine porphobilinogen test is indicated.

Another benefit of identifying such patients is to inform local specialists of the presence of patients with rare diseases in which they have expertise. An institution-wide search for confirmed AHP patients through our targeted ICD-10-CM code search plus manual chart review identified 30 confirmed AHP patients. A majority of these patients were previously unknown to the porphyria specialist (TD) at OHSU. Identifying rare disease patients through large-scale data review in this manner can help connect them with the appropriate specialist to ensure optimal care.

Our results strongly suggest that leveraging of EHR data coupled with machine learning can be an effective method of identifying patients who should receive a diagnostic biochemical test to screen for AHP. Our approach was able to identify patients with compelling constellations of symptoms who had not be previously worked up for porphyria. It was also able to identify patients for whom porphyria had been considered without direct access to porphyria-related data elements such as hemin treatment, lab tests specific to AHP, or mention of AHP diagnosis in clinical notes.

This is especially interesting in the light that the overall cross-validation scores of the model on the data set using the known 30 AHP cases as the positive set and the rest of the data as negative training samples was not very high, with cross-validation yielding an average AUC = 0.775. This is somewhat of a lower performance figure then we initially expected. However, this task is very different from typical machine learning tasks due to the extremely rare nature of the positive AIP cases in both the training data as well as in the actual patient population. In most machine learning research, a data set is considered skewed or imbalanced if the number of positive cases is much less than 50%. A recent systematic review on imbalanced data classification cites articles investigating negative to positive case ratios of 100 to 1 as “highly imbalanced” (27, 28). For problems such as rare diseases, the imbalance ratio can be nearly 10,000 to 1, as it is here. Lifting the predictive power to perhaps 22 in 100 manually reviewed cases is a potentially transformative level of performance.

The strongest positive predictors in the model included unexplained abdominal pain, pelvic and perineal pain, nausea and vomiting, and a number of pain and nausea medications. Frequent urinalysis was also a strong positive predictive feature, this is likely due to being associated with frequent ER visits and hospitalizations. The model relied on encoding the frequency of episodes, and not just binary presence of absence of symptoms. Indirectly, in the model this represented recurrent, undiagnosed problems consistent with AHP. Abdominal pain with unremarkable abdominal exam is reported as one of the most common presenting symptoms of AHP [21]. One recent cohort study also identifies nausea as significantly associated with recurrent attacks of AHP [23]. Acute pain management with opiods is also part of recent therapeutic recommendations [24].

As these methods are general, and not specific to AHP, they could be applicable to other rare disorders that have a constellation of recurrent symptoms as indicating features. There are likely ways to improve the machine learning approach, including the use of more advanced features that represent time, duration, and intervals, explicit coding of symptom separation and overlap, and more sophisticated machine learning algorithms specifically tailored to situations where the positive case is extremely rare. Investigation into machine learning algorithms for highly skewed data such as these is an active area of research [25].

Conclusion

The combination of large data sets, machine learning techniques, and clinical knowledge engineering can be a powerful tool to identify patients with undiagnosed rare diseases. The use case of AHP presented here revealed four undiagnosed patients thought likely to have AHP, as well as 18 others who would likely benefit from testing. This level of precision in identifying potential cases of AHP from EHR data is much higher than would be expected by the prevalence of the disease.

Analyzing the EHR with advanced techniques such as demonstrated here points to the potential of the future of digital medicine on a population scale. Advanced approaches enabled by the wide deployment of the EHR can now be used to improve medicine and medical care in areas that have been underserved or inaccessible. Health care can be made more proactive, not simply in terms of common conditions and age or gender related screening, but for rarer conditions as well.

We plan to continue this work in several directions. First, it is essential for work like this to be deployed and evaluated in a clinical setting. An IRB-approved clinical validation study is being implemented. In this study, we will contact the primary care clinicians (PCP) of the patients where AHP diagnostic testing was found to be likely or possibly indicated. We will inform them that an algorithm based on EHR data has determined that their patient might have AHP and could benefit from a spot urine porphobilinogen, which is an is inexpensive, non-invasive and easy to perform diagnostic test. With the agreement of the PCP, we will then contact patients and offer them the test. Expert clinical consultation will be made available to the PCP for any questions they have. We will collect data on the interactions with the PCPs, the number of spot urine porphobilinogen tests administered, as well as the test results. In this manner, we will be able to study the clinical impact of our rare disease identification approach, beyond the retrospective, data-only study conducted and presented here.

Second, we will continue to refine our methods. Other machine learning algorithms, such as random forests and deep learning, may have advantages for AHP and other rare diseases. Other methods of encoding the EHR data that incorporate embeddings and temporal representations, have been shown to demonstrate leading-edge results in other fields, such as computer vision, machine translation, and speech recognition, and may assist with rare diseases.

Finally, we will extend this methodology to other rare diseases that are difficult to diagnose, focusing on those for which effective treatments are becoming available. If the timeline for diagnosing rate conditions can be substantially reduced, there is great potential to impact patient health in a very significant manner.

Supporting information

S1 Table. Final 141 features selected for inclusion in the machine learning model to predict acute hepatic porphyria.

Features are scored by number of occurrances in an individual patient medical record, and then normalized.

(DOCX)

Click here for additional data file.^{(22.4KB, docx)}

Data Availability

The source data used for this project is electronic health record (EHR) data, and contains protected health information (PHI) for patients under care at Oregon Health & Science University (OHSU). The OHSU Institutional Review Board (IRB) does not allow release of this data to the public, and doing so would violate US HIPAA laws. The OHSU IRB can be contacted at: irb@ohsu.edu. Questions about data requests may be sent to this address. We are including full details of the machine learning model, training methods, and final features. Other investigators experienced in the field should be able to reproduce our methods on their own data to validate the results presented in this manuscript.

Funding Statement

AMC, BH, SC, and MN received support for this work from Alnylam Pharmaceuticals, Inc., Cambridge, MA. SM, JJK, JJA and AJW are/were employees of Alnylam Pharmaceuticals, Inc., Cambridge, MA during the time of this research. This work was funded and the associated editorial support was provided by Alnylam Pharmaceuticals, Inc., Cambridge, MA. Grant number 4510005336 https://www.alnylam.com/ Alnylam participated in algorithm design and preparation of the manuscript. They had no role in the evaluation or EHR data collection and analysis, nor did they have any access to the individual patient electronic health record data used in this research.

References

1.Meystre SM, Lovis C, Bürkle T, Tognola G, Budrionis A, Lehmann CU. Clinical data reuse or secondary use: current status and potential future progress. Yearbook of medical informatics. 2017;26(01):38–52. [DOI] [PMC free article] [PubMed] [Google Scholar]
2.Haendel M, Vasilevsky N, Unni D, Bologa C, Harris N, Rehm H, et al. How many rare diseases are there? Nat Rev Drug Discov. 2020;19(2):77–8. 10.1038/d41573-019-00180-y [DOI] [PMC free article] [PubMed] [Google Scholar]
3.Ramalle-Gómara E, Ruiz E, Quiñones C, Andrés S, Iruzubieta J, Gil-de-Gómez J. General knowledge and opinion of future health care and non-health care professionals on rare diseases. J Eval Clin Pract. 2015. April;21(2):198–201. 10.1111/jep.12281 [DOI] [PubMed] [Google Scholar]
4.Garg R, Dong S, Shah S, Jonnalagadda SR. A bootstrap machine learning approach to identify rare disease patients from electronic health records. arXiv preprint arXiv:160901586. 2016.
5.Colbaugh R, Glass K, Rudolf C, Global MTV. Learning to Identify Rare Disease Patients from Electronic Health Records. In: AMIA Annual Symposium Proceedings. American Medical Informatics Association; 2018. p. 340. [PMC free article] [PubMed]
6.Shen F, Wang L, Liu H. Phenotypic Analysis of Clinical Narratives Using Human Phenotype Ontology. Studies in health technology and informatics. 2017;245:581–5. [PMC free article] [PubMed] [Google Scholar]
7.Shen F, Liu S, Wang Y, Wen A, Wang L, Liu H. Utilization of electronic medical records and biomedical literature to support the diagnosis of rare diseases using data fusion and collaborative filtering approaches. JMIR medical informatics. 2018;6(4):e11301 10.2196/11301 [DOI] [PMC free article] [PubMed] [Google Scholar]
8.Besur S, Hou W, Schmeltzer P, Bonkovsky HL. Clinically important features of porphyrin and heme metabolism and the porphyrias. Metabolites. 2014;4(4):977–1006. 10.3390/metabo4040977 [DOI] [PMC free article] [PubMed] [Google Scholar]
9.Gouya L, Ventura P, Balwani M, Bissell DM, Rees DC, Stölzel U, et al. EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks. Hepatology. 2020. May;71(5):1546–58. 10.1002/hep.30936 [DOI] [PMC free article] [PubMed] [Google Scholar]
10.Bissell DM, Anderson KE, Bonkovsky HL. Porphyria. N Engl J Med. 2017. August 31;377(9):862–72. 10.1056/NEJMra1608634 [DOI] [PubMed] [Google Scholar]
11.Ramanujam V-MS, Anderson KE. Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias. Curr Protoc Hum Genet. 2015. July 1;86:17.20.1–17.20.26. [DOI] [PMC free article] [PubMed] [Google Scholar]
12.Szlendak U, Bykowska K, Lipniacka A. Clinical, Biochemical and Molecular Characteristics of the Main Types of Porphyria. Adv Clin Exp Med. 2016. April;25(2):361–8. 10.17219/acem/58955 [DOI] [PubMed] [Google Scholar]
13.Elder G, Harper P, Badminton M, Sandberg S, Deybach J-C. The incidence of inherited porphyrias in Europe. J Inherit Metab Dis. 2013. September;36(5):849–57. 10.1007/s10545-012-9544-4 [DOI] [PubMed] [Google Scholar]
14.Bonkovsky HL, Maddukuri VC, Yazici C, Anderson KE, Bissell DM, Bloomer JR, et al. Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium. Am J Med. 2014. December;127(12):1233–41. 10.1016/j.amjmed.2014.06.036 [DOI] [PMC free article] [PubMed] [Google Scholar]
15.Chen B, Solis‐Villa C, Hakenberg J, Qiao W, Srinivasan RR, Yasuda M, et al. Acute intermittent porphyria: predicted pathogenicity of HMBS variants indicates extremely low penetrance of the autosomal dominant disease. Human mutation. 2016;37(11):1215–22. 10.1002/humu.23067 [DOI] [PMC free article] [PubMed] [Google Scholar]
16.Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med. 2005. March 15;142(6):439–50. 10.7326/0003-4819-142-6-200503150-00010 [DOI] [PubMed] [Google Scholar]
17.Pischik E, Kauppinen R. An update of clinical management of acute intermittent porphyria. The application of clinical genetics. 2015;8:201 10.2147/TACG.S48605 [DOI] [PMC free article] [PubMed] [Google Scholar]
18.PANHEMATIN^® (hemin for injection) Official Treatment Website [Internet]. [cited 2020 Jun 11]. https://www.panhematin.com/
19.Sardh E, Harper P, Balwani M, Stein P, Rees D, Bissell DM, et al. Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria. New England Journal of Medicine. 2019. February 7;380(6):549–58. 10.1056/NEJMoa1807838 [DOI] [PubMed] [Google Scholar]
20.Research C for DE and. Drug Trials Snapshots: GIVLAARI. FDA [Internet]. 2020 Jan 27 [cited 2020 Jun 11]; https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-givlaari
21.Porphyrias: An overview—UpToDate [Internet]. [cited 2020 Jun 11]. https://www.uptodate.com/contents/porphyrias-an-overview?search=Porphyrias:%20An%20overview&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1
22.Cherem JH, Malagon J, Nellen H. Cimetidine and acute intermittent porphyria. Annals of internal medicine. 2005;143(9):694 10.7326/0003-4819-143-9-200511010-00023 [DOI] [PubMed] [Google Scholar]
23.Neeleman RA, Wagenmakers MAEM, Koole-Lesuis RH, Mijnhout GS, Wilson JHP, Friesema ECH, et al. Medical and financial burden of acute intermittent porphyria. J Inherit Metab Dis. 2018;41(5):809–17. 10.1007/s10545-018-0178-z [DOI] [PMC free article] [PubMed] [Google Scholar]
24.Cardenas JL, Guerrero C. Acute intermittent porphyria: general aspects with focus on pain. Curr Med Res Opin. 2018;34(7):1309–15. 10.1080/03007995.2018.1435521 [DOI] [PubMed] [Google Scholar]
25.Haixiang G, Yijing L, Shang J, Mingyun G, Yuanyue H, Bing G. Learning from class-imbalanced data: Review of methods and applications. Expert Systems with Applications. 2017;73:220–39. [Google Scholar]

PLoS One. doi: 10.1371/journal.pone.0235574.r001

Decision Letter 0

Sreeram V Ramagopalan

Transfer Alert

This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.

5 May 2020

PONE-D-20-10338

Detecting Rare Diseases in Electronic Health Records Using Machine Learning and Knowledge Engineering: Case Study of Acute Hepatic Porphyria

PLOS ONE

Dear Dr. Cohen,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Jun 19 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.
A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.
An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Sreeram V. Ramagopalan

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

1. Thank you for inlcuding your competing interests statement; "I have read the journal's policy and the authors of this manuscript have the following competing interests:

GIVLAARI is a product of Alnylam. GIVLAARI is a prescription medicine used to treat acute hepatic porphyria (AHP) in adults."

We note that you received funding from a commercial source:Alnylam Pharmaceuticals, Inc.

Please provide an amended Competing Interests Statement that explicitly states this commercial funder, along with any other relevant declarations relating to employment, consultancy, patents, products in development, marketed products, etc.

Within this Competing Interests Statement, please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests). If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your amended Competing Interests Statement within your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

2. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: No

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The abstract for this article is clear and concise, however the methods are unclear and difficult to follow. The methods section should provide a clear progression of logic as to how the study was conducted, ideally in linear, step-by-step fashion. Results, including from data cleaning, chart review and model parameter selection should not be included in the methods section. While the authors note that this article is a case study, the methods should nonetheless follow an a priori format. Any testing, manual review and experimenting on model structure, test statistics, etc. should be noted in the methods (ideally with a brief rationale or reference), and the results from these steps presented in the results. I believe this article can be improved, as the authors have clearly performed a considerable amount of analyses to understand prognostic features in EHR data for AHP, but without a clearly-outlined methodology I cannot evaluate the results.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: PONE-D-20-10338_reviewer comments.pdf

Click here for additional data file.^{(904.7KB, pdf)}

PLoS One. 2020 Jul 2;15(7):e0235574. doi: 10.1371/journal.pone.0235574.r002

Author response to Decision Letter 0

15 May 2020

Reviewer comments and our responses are given in our response letter and more conveniently formatted than are shown here.

While this is important background it is not clear if this paragraph is needed in the paper, other than noting the diagnostic/prognostics should rely on biomarker and other lab tests rather than family history. Consider removing, or condensing.

This paragraph of text is important to provide the patient disease context for our work, and provides additional clinical and genetic background to orient readers who may not have expertise about this disease, such as informaticians and machine learning researchers. The difficult diagnosis of AHP is in part due to the disease low penetrance and inconsistent appearances in families even though AHP and related diseases are mostly autosomal dominant. We therefore would like to keep the paragraph that is there now, as it really does not substantially lengthen the paper.

Recommend adding the number of patients with ICD-10 code E80.21.

This has been done.

Unique patients, or unique records/document counts? And if document counts, is this the number of unique documents with a specific code? Please clarify.

Total number of EHR records? Please clarify.

We have modified the table and caption to make these points clear.

This section is better-suited under the methods section below. Please update.

Moved as requested.

What is the start date of the data pull? How historical is the cohort?

This information has been added.

Typo? This sentence is a little confusing. Consider revising to "... adequate sample size to make predictive models robust..."

Revised as suggested.

Was this a wildcard text search? Please clarify

These are wildcard search terms, clarified in the text as requested.

You state "high likelihood" but below you note the chart review looked for a positive confirmation of AHP. It sounds like you are in fact confirming AHP through manual chart review.

This is correct. Thank you for identifying this confusion. We have revised the text to:

The remaining 17 records? Please specify.

Added clarifying text:

For the remaining 17 records, we could not confirm by chart review the diagnosis of AHP. This may be due to the code being attached to the patient based on an encounter to rule out AHP, or a charting error. For these 17 patients no additional information supporting the AHP diagnosis was found in the notes, clinical tests or medication records and the only evidence of AHP was a code in the problem list or encounter diagnosis.

Results, not methods

Results of model building, not methods.

The corresponding text has been moved to the results section, and the results section reorganized to incorporate the new text.

Model? Spelling?

Thank you for finding this error. Changed word to “algorithm”.

What is a source document? The location the field is derived in the EHR? Wouldn't that location depend on the underlying EHR structure? And why is the source document location important?

Yes, the source document is dependent upon the underlying structure of the EHR, and of our data warehouse as well. As the EHR itself is a hierarchical patient-oriented database, and our RDW is a relational database extract of that, we have no choice but to treat the records in units corresponding to the structure of the extract. These mappings between the EHR that clinicians use and the data extracts available to investigators is a common situation. The source document types correspond to units of observation common in documenting clinical care electronically. Our feature set provides both the source document and specific data field used in the model in order to provide as much information as possible to anyone trying to repeat our work and perform a similar mapping with their own EHR data. We have tried to make this more clear both in the descriptions, tables, and supplementary data.

There is no mention of constructing a training dataset in this section until the very end.

Thank you for pointing this out. We have added text to clarify how the data was used:

Why four patients? What was the rationale for this threshold?

Added text:

Requiring that included feature have at least four positive case patient records was chosen as a filter to strike a balance between only keeping the most common features, and keeping thousands of rare features requiring manual review that were unlikely be helpful in a generalized model.

What is the manual review process? Why not simply exclude features for EHR records that also have a corresponding AHP diagnosis, mention or treatment?

We could not exclude features as suggested since this criterion would not remove all the biased features and it may remove some associated unbiased features that could be useful.

Added: This was done by inspection using clinical domain knowledge.

How is this process different from the previous "manual review process"? Also, wouldn't the first review (if manual) have identified these same AHP-correlated features?

We needed a second pass, which included a clinical porphyria expert, to ensure that we did not miss any features that were biased by clinical pre-existing knowledge of a diagnosis of porphyria for the patient.

Added text:

This second pass incorporated a higher level of clinical expertise than the first pass. It was performed after filtering by SVM weight in order to reduce the screening load on our clinical expert.

I would expect the results section to begin with this number, highlighting the total number of patients in the entire dataset, then the final number of patients used for subsequent analyses.

Moved this text to the beginning of the results section.

General comment on all tables- please update the tables so they share the same format throughout the paper (e.g. font, font size, bold use, number formats).

We have reformatted the tables to use a consistent style.

Total number of EHR records? Please clarify.

Total number of EHR documents and patient records added to caption for Table 2.

Unique patients, or unique records/document counts? And if document counts, is this the number of unique documents with a specific code? Please clarify.

Clarified in table caption and column headings.

Please spell out the document types. The current list appears to be table names from the database itself. For example, "current_medications" should be renamed "Concomitant Medications" or "Poly-Pharmacy". "demographics" should be "Patient Demographics". I also recommend providing a brief description of these fields, as some readers may not be as familiar with traditional EHR domains.

I recommend including standard deviation with any results presenting Mean.

Finally, be sure to format the table numbers (some rows appear to have comma delimiters, others do not).

Table 3 document type names changed to correspond with the document types in Table 1. Reformatted numbers to not use commas.

Table has been reformatted to be consistent and use full document names. Data dictionary definitions of the document types has been added to Table 1 to describe what is in these documents. Mean has been removed as table is too wide with the additions and larger font. Median and max remain and are sufficiently informative for this purpose.

Please provide either a data dictionary with descriptions for each feature, or update this table with descriptions of each feature. The current format requires the reader to assume what each feature represents based on the feature dataset name, but formal descriptions would provide more explicit clarity for the reader.

Table has been reformatted and extended to include data descriptions.

PLoS One. doi: 10.1371/journal.pone.0235574.r003

Decision Letter 1

Sreeram V Ramagopalan

26 May 2020

PONE-D-20-10338R1

Detecting Rare Diseases in Electronic Health Records Using Machine Learning and Knowledge Engineering: Case Study of Acute Hepatic Porphyria

PLOS ONE

Dear Dr. Cohen,

Please submit your revised manuscript by Jul 10 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Sreeram V. Ramagopalan

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

Reviewer #1: Yes

**********

6. Review Comments to the Author

Reviewer #1: The revision has addressed many of the initial comments. I have provided additional comments in the attached document for your review. There are a few structural changes I'd like to recommend to strengthen the clarity of the manuscript, as well as answer questions surrounding the methods and results.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: PONE-D-20-10338_R1_reviewer_comments.pdf

Click here for additional data file.^{(1.4MB, pdf)}

PLoS One. 2020 Jul 2;15(7):e0235574. doi: 10.1371/journal.pone.0235574.r004

Author response to Decision Letter 1

16 Jun 2020

Here is the plain text of the response to reviewer comments as presented in the cover letter. The formatting is easier to follow in the attached cover letter.

June 16, 2020

Dear PLOS One Editors:

Please find attached a re-revised draft of our manuscript “Detecting Rare Diseases in Electronic Health Records Using Machine Learning and Knowledge Engineering: Case Study of Acute Hepatic Porphyria”. We have made additional changes based on the second round of reviewer feedback. Please thank the reviewer(s) for their helpful comments and identification of points of confusion and suggestions for clarifying the manuscript further.

We provide detailed point-by-point responses to the reviewer’s comments below.

Sincerely,

Aaron M. Cohen, MD MS

Professor

Department of Medical Informatics and Clinical Epidemiology

Oregon Health & Science University

Portland, Oregon USA 97239

Reviewer comments are shown in bold, our responses are given immediately afterword in plain font.

2020-05-18 18:04:31

--------------------------------------------

The background information on rare diseases in general and AHP in particular is very good, however the link between rare disease identification in EHRs and the machine learning approach noted in the abstract should be strengthened. Specifically, a final paragraph highlighting the gap in current research in this area (e.g. where is current research in EHR/AHP/machine learning lacking?) , as well as the goal of this study as it related to these gaps in the research (e.g. why is this study being conducted? What gaps in the sciene will this study fill?).

Thank you for this suggestion. We agree that the abstract does not make this connection clear. We have extended the last paragraph in the abstract to make these connections clearer. We would like to add more detail in the area but we are at the 500-word limit of the abstract.

Conclusions

2020-05-18 18:05:23

--------------------------------------------

Consider moving IRB statement to the very end of methods section.

We have moved the IRB statement to the end of the methods section as suggested.

2020-05-18 23:36:04

--------------------------------------------

I recommend making the dataset section the last section in the methods. Present the Machine learning methodology first, then feature selection, then the data.

Because the feature encoding and selection method descriptions, as well as our cohort analysis method, rely somewhat on the descriptions of the data in the dataset section, we think that it is clearer to keep the order as it is.

2020-05-18 18:43:58

--------------------------------------------

This belongs at the end of the introduction, not the methods section.

Moved to the end of the Introduction as suggested.

2020-05-22 23:13:54

--------------------------------------------

Where do these 5,571 patients come from? Are they a subset of the 200k from RDW, or some other EHR data source? Please specify.

They come from the same data source and were pulled from the RDW at the same time.

To clarify this we have added the text:

2020-05-25 14:54:31

--------------------------------------------

Why univariate? Given many of these features may have correlation, why not a multivariate model? Please provide rationale.

Added an explanatory sentence in this paragraph:

2020-05-22 23:18:13

--------------------------------------------

Consider revising to "burden of manual chart review"

Changed as suggested.

2020-05-22 23:19:31

--------------------------------------------

An alternative/complimentary method could be a randomly selected subset of patients for chart review

Thank you for the suggestion. We have added the following text as a rationale.

An alternative method would be a randomly selected subset of patients for chart review. However, because AHP is such as rare disease, the probability of finding even a single positive case with random sampling would is very small, about 0.05%.

2020-05-22 23:44:43

--------------------------------------------

What was the decision boundary for the model?

We have added a sentence stating the boundary size:

Standard SVM boundary settings were used, keeping samples scores inside the boundary region within the interval [-1, +1].

2020-05-22 23:46:56

--------------------------------------------

The patients were sorted by classifier margin distance and the first 100 in each group were selected?

Yes, that is correct.

2020-05-22 23:39:47

--------------------------------------------

How is this model automated? It seems there is considerable manual processes involved.

We agree, ‘automated model’ is not the right term here. Changed to ‘our approach’.

2020-05-22 23:36:40

--------------------------------------------

The studies cited here do not perform the same type of analysis, making comparisons to the author's AUC irrelevant. I recommend deleting, or revising with specific AUC results from studies predicting rare diseases.

Removed the comparison text and revised the paragraph as follows:

2020-05-22 23:47:48

--------------------------------------------

Are there population-based studies of patients with AHP that identify these conditions/diagnoses as predictors as well? Anderson (2019) is cited above and may also be applicable here. This would strengthen the authors' results.

Added references to Anderson (2019) and other studies with some similar findings to the discussion. Thank you for the suggestion.

2020-05-22 23:33:37

--------------------------------------------

Could

Thank you. Changed ‘should’ to ‘could’.

2020-05-22 23:33:04

--------------------------------------------

This section reads more like a grant application. I recommend deleting, or summarizing more broadly as areas to continue the research.

We have made a small addition to the text to clarify our intent, but we do not think substantial changes to these three paragraphs are necessary. We believe it is important for us to convey these specific future directions for this work. They provide an important perspective on where research like this should head after the initial phase described in this paper. The text also highlights the importance of clinical evaluation and follow up of informatics and machine learning research to produce improvement in patient care.

2020-05-22 23:31:03

--------------------------------------------

Could tables 5-9 be combined into one table?

We think it would be very dense and confusing to combine all these tables into one table. The individual captions help to explain the tables and what they present in a focused manner. Also the font size would have to be shrunk and that would make readability difficult.

Also, tables 5-6 present patient subgroups on the horizontal rows, while tables 7-8 present the patient subgroups in the vertical columns. I reccomend picking one or the other and applying to all tables.

We have changed tables 7 and 8 to present patient subgroups in horizontal rows.

2020-05-22 23:28:29

--------------------------------------------

Each patient group (e.g. clinical notes and no mention of porphyria)?

Changed to ‘each’ as suggested.

2020-05-22 23:26:35

--------------------------------------------

Each patient group (e.g. clinical notes and no mention of porphyria)?

Changed to ‘each’ as suggested.

2020-05-22 23:29:10

--------------------------------------------

Generally, standard deviation is presented with mean

We have included a column for standard deviation.

PLoS One. doi: 10.1371/journal.pone.0235574.r005

Decision Letter 2

Sreeram V Ramagopalan

18 Jun 2020

Detecting Rare Diseases in Electronic Health Records Using Machine Learning and Knowledge Engineering: Case Study of Acute Hepatic Porphyria

PONE-D-20-10338R2

Dear Dr. Cohen,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Sreeram V. Ramagopalan

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

PLoS One. doi: 10.1371/journal.pone.0235574.r006

Acceptance letter

Sreeram V Ramagopalan

23 Jun 2020

PONE-D-20-10338R2

Detecting Rare Diseases in Electronic Health Records Using Machine Learning and Knowledge Engineering: Case Study of Acute Hepatic Porphyria

Dear Dr. Cohen:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Sreeram V. Ramagopalan

Academic Editor

PLOS ONE

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

S1 Table. Final 141 features selected for inclusion in the machine learning model to predict acute hepatic porphyria.

Features are scored by number of occurrances in an individual patient medical record, and then normalized.

(DOCX)

Click here for additional data file.^{(22.4KB, docx)}

Attachment

Submitted filename: PONE-D-20-10338_reviewer comments.pdf

Click here for additional data file.^{(904.7KB, pdf)}

Attachment

Submitted filename: PONE-D-20-10338_R1_reviewer_comments.pdf

Click here for additional data file.^{(1.4MB, pdf)}

Data Availability Statement

[pone.0235574.ref001] 1.Meystre SM, Lovis C, Bürkle T, Tognola G, Budrionis A, Lehmann CU. Clinical data reuse or secondary use: current status and potential future progress. Yearbook of medical informatics. 2017;26(01):38–52. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0235574.ref002] 2.Haendel M, Vasilevsky N, Unni D, Bologa C, Harris N, Rehm H, et al. How many rare diseases are there? Nat Rev Drug Discov. 2020;19(2):77–8. 10.1038/d41573-019-00180-y [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0235574.ref003] 3.Ramalle-Gómara E, Ruiz E, Quiñones C, Andrés S, Iruzubieta J, Gil-de-Gómez J. General knowledge and opinion of future health care and non-health care professionals on rare diseases. J Eval Clin Pract. 2015. April;21(2):198–201. 10.1111/jep.12281 [DOI] [PubMed] [Google Scholar]

[pone.0235574.ref004] 4.Garg R, Dong S, Shah S, Jonnalagadda SR. A bootstrap machine learning approach to identify rare disease patients from electronic health records. arXiv preprint arXiv:160901586. 2016.

[pone.0235574.ref005] 5.Colbaugh R, Glass K, Rudolf C, Global MTV. Learning to Identify Rare Disease Patients from Electronic Health Records. In: AMIA Annual Symposium Proceedings. American Medical Informatics Association; 2018. p. 340. [PMC free article] [PubMed]

[pone.0235574.ref006] 6.Shen F, Wang L, Liu H. Phenotypic Analysis of Clinical Narratives Using Human Phenotype Ontology. Studies in health technology and informatics. 2017;245:581–5. [PMC free article] [PubMed] [Google Scholar]

[pone.0235574.ref007] 7.Shen F, Liu S, Wang Y, Wen A, Wang L, Liu H. Utilization of electronic medical records and biomedical literature to support the diagnosis of rare diseases using data fusion and collaborative filtering approaches. JMIR medical informatics. 2018;6(4):e11301 10.2196/11301 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0235574.ref008] 8.Besur S, Hou W, Schmeltzer P, Bonkovsky HL. Clinically important features of porphyrin and heme metabolism and the porphyrias. Metabolites. 2014;4(4):977–1006. 10.3390/metabo4040977 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0235574.ref009] 9.Gouya L, Ventura P, Balwani M, Bissell DM, Rees DC, Stölzel U, et al. EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks. Hepatology. 2020. May;71(5):1546–58. 10.1002/hep.30936 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0235574.ref010] 10.Bissell DM, Anderson KE, Bonkovsky HL. Porphyria. N Engl J Med. 2017. August 31;377(9):862–72. 10.1056/NEJMra1608634 [DOI] [PubMed] [Google Scholar]

[pone.0235574.ref011] 11.Ramanujam V-MS, Anderson KE. Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias. Curr Protoc Hum Genet. 2015. July 1;86:17.20.1–17.20.26. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0235574.ref012] 12.Szlendak U, Bykowska K, Lipniacka A. Clinical, Biochemical and Molecular Characteristics of the Main Types of Porphyria. Adv Clin Exp Med. 2016. April;25(2):361–8. 10.17219/acem/58955 [DOI] [PubMed] [Google Scholar]

[pone.0235574.ref013] 13.Elder G, Harper P, Badminton M, Sandberg S, Deybach J-C. The incidence of inherited porphyrias in Europe. J Inherit Metab Dis. 2013. September;36(5):849–57. 10.1007/s10545-012-9544-4 [DOI] [PubMed] [Google Scholar]

[pone.0235574.ref014] 14.Bonkovsky HL, Maddukuri VC, Yazici C, Anderson KE, Bissell DM, Bloomer JR, et al. Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium. Am J Med. 2014. December;127(12):1233–41. 10.1016/j.amjmed.2014.06.036 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0235574.ref015] 15.Chen B, Solis‐Villa C, Hakenberg J, Qiao W, Srinivasan RR, Yasuda M, et al. Acute intermittent porphyria: predicted pathogenicity of HMBS variants indicates extremely low penetrance of the autosomal dominant disease. Human mutation. 2016;37(11):1215–22. 10.1002/humu.23067 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0235574.ref016] 16.Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med. 2005. March 15;142(6):439–50. 10.7326/0003-4819-142-6-200503150-00010 [DOI] [PubMed] [Google Scholar]

[pone.0235574.ref017] 17.Pischik E, Kauppinen R. An update of clinical management of acute intermittent porphyria. The application of clinical genetics. 2015;8:201 10.2147/TACG.S48605 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0235574.ref018] 18.PANHEMATIN^® (hemin for injection) Official Treatment Website [Internet]. [cited 2020 Jun 11]. https://www.panhematin.com/

[pone.0235574.ref019] 19.Sardh E, Harper P, Balwani M, Stein P, Rees D, Bissell DM, et al. Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria. New England Journal of Medicine. 2019. February 7;380(6):549–58. 10.1056/NEJMoa1807838 [DOI] [PubMed] [Google Scholar]

[pone.0235574.ref020] 20.Research C for DE and. Drug Trials Snapshots: GIVLAARI. FDA [Internet]. 2020 Jan 27 [cited 2020 Jun 11]; https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-givlaari

[pone.0235574.ref021] 21.Porphyrias: An overview—UpToDate [Internet]. [cited 2020 Jun 11]. https://www.uptodate.com/contents/porphyrias-an-overview?search=Porphyrias:%20An%20overview&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1

[pone.0235574.ref022] 22.Cherem JH, Malagon J, Nellen H. Cimetidine and acute intermittent porphyria. Annals of internal medicine. 2005;143(9):694 10.7326/0003-4819-143-9-200511010-00023 [DOI] [PubMed] [Google Scholar]

[pone.0235574.ref023] 23.Neeleman RA, Wagenmakers MAEM, Koole-Lesuis RH, Mijnhout GS, Wilson JHP, Friesema ECH, et al. Medical and financial burden of acute intermittent porphyria. J Inherit Metab Dis. 2018;41(5):809–17. 10.1007/s10545-018-0178-z [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0235574.ref024] 24.Cardenas JL, Guerrero C. Acute intermittent porphyria: general aspects with focus on pain. Curr Med Res Opin. 2018;34(7):1309–15. 10.1080/03007995.2018.1435521 [DOI] [PubMed] [Google Scholar]

[pone.0235574.ref025] 25.Haixiang G, Yijing L, Shang J, Mingyun G, Yuanyue H, Bing G. Learning from class-imbalanced data: Review of methods and applications. Expert Systems with Applications. 2017;73:220–39. [Google Scholar]

PERMALINK

Detecting rare diseases in electronic health records using machine learning and knowledge engineering: Case study of acute hepatic porphyria

Aaron M Cohen

Steven Chamberlin

Thomas Deloughery

Michelle Nguyen

Steven Bedrick

Stephen Meninger

John J Ko

Jigar J Amin

Alex J Wei

William Hersh

Roles

Abstract

Background

Methods and findings

Conclusions

Introduction

Materials and methods

Dataset

Table 1. Electronic Health Record (EHR) document types used in this research.

Table 2. Electronic Health Record (EHR) total document and unique patients counts of porphyria codes and mentioned in text notes or label tests.

Table 3. Summary of document types and counts used in the EHR data set for this research.

Feature selection and machine learning methods

Machine learning for AHP prediction and evaluation methodology

Results

Final selected features and machine learning cross-validation

Fig 1. Flowchart of patient data record selection.

Table 4. Cross-validation performance of the final feature set on the entire data set for ranking the 30 confirmed cases of porphyria higher than the general population.

Application of machine learning to the full data set

Table 5. Assessment of the likelihood of undiagnosed acute hepatic porphyria based on clinical note symptom documentation.

Table 6. Top alternative explanations for AHP symptom profiles seen in each group of patients.

Table 7. Age statistics in years for each of the two patient groups.

Table 8. Sex distribution for each of the two patient groups.

Table 9. Top reasons for the presence of the word ‘porph’ found in the clinical note.

Discussion

Conclusion

Supporting information

Data Availability

Funding Statement

References

Decision Letter 0

Sreeram V Ramagopalan

Roles

Transfer Alert

Author response to Decision Letter 0

Decision Letter 1

Sreeram V Ramagopalan

Roles

Author response to Decision Letter 1

Decision Letter 2

Sreeram V Ramagopalan

Roles

Acceptance letter

Sreeram V Ramagopalan

Roles

Associated Data

Supplementary Materials

Data Availability Statement

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases